Brief vs. extended buprenorphine detoxification in a community treatment program: Engagement and short-term outcomes

American Journal of Drug and Alcohol Abuse

Volumn 35, Issue 2, 2009, Pages 63-67

  Katz, Elizabeth C ^a,b   Schwartz, Robert P ^b   King, Stuart ^b   Highfield, David A ^c   O'Grady, Kevin E ^d   Billings, Timothy ^a   Gandhi, Devang ^e   Weintraub, Eric ^e   Glovinsky, David ^e   Barksdale, Wardell ^e,f   Brown, Barry S ^b,g  

^a TOWSON UNIVERSITY   (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c Harry and Jeannette Weinberg Cancer Center   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f Harambee Treatment Center   (United States)

^g UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

Author keywords

Buprenorphine; Engagement; Opiate Detoxification; Treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; OPIATE; BUPRENORPHINE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; DRUG DETOXIFICATION; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTPATIENT DEPARTMENT; PATIENT COUNSELING; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; COUNSELING; DRUG ADMINISTRATION; DRUG DEPENDENCE TREATMENT; MIDDLE AGED; STATISTICS; SUBSTANCE ABUSE; TIME; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; COUNSELING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 65549093736     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802585380     Document Type: Article

References (27)

1. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights-2006. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-40, DHHS Publication No. (SMA) 08-4313, Rockville, MD, Table 4.
2. Becker A, Strain E, Bigelow G, Stitzer M, Johnson R. Gradual dose taper following chronic buprenorphine. The American Journal on Addictions 2001; 10:111-121.
3. Greenwald M, Schuh K, Stine S. Transferring Methadone-maintained outpatients to the buprenorphine sublingual tablet: A preliminary study. The American Journal on Addictions 2003; 12:365-374.
4. Bell J, ByronG,GibsonA,MorrisA.Apilot study of buprenorphine- naloxone combination tablet (Suboxone R ) in treatment of opioid dependence. Drug and Alcohol Review 2004; 23:311-317.
5. Collins E, Kleber H, Whittington R, Heitler N. Anesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: A randomized trial. The Journal of the American Medical Association 2005; 294:903-913.
6. Gandhi D, Jaffe J,McNary S,KavanaghG,Hayes M, Currens M. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003; 98:453-462.
7. Amass L, Bickel WK, Higgins S, Hughes J. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Disease 2005; 13:33-45.
8. Diamant K, Fischer G, Schneider C, Lenzinger E, Pezawas L, Schindler S, Eder H. Out-patient opiate detoxification treatment with buprenorphine. European Addictions Research 1998; 4:198-202.
9. Gibson A, Doran C, Bell J, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: A randomized trial. The Medical Journal of Australia 2003; 170:38-42. (Pubitemid 36896192)
10. LingW, Amass L, ShoptawS, Annon JJ, HillhouseM, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D,Woody G, Krejci J, Ziedonis D. The Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphone-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug AbuseClinical Trials Network. Addiction 2005; 100:1090-1100.
11. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002; 97:1395-1404.
12. Seifert J,Metzner C, PaetzoldW, MorsutzkyM, Passie T, Rollnick J,Wises B, Emrich HM, Schneider U. Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35:159-164.
13. Vignau J. Preliminary assessment of a 10-day rapid detoxification program using high dosage buprenorphine. European Addiction Research 1998; 1(Suppl. 4):29-31.
14. Digusto E, Lintzeris N, Breen C, Kimber J, Mattick R, Bell J, Ali R, Saunders JB. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD project. Addictive Behaviors 2005; 30:443-456.
15. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioiddependent adolescents: A randomized controlled trial. Archives of General Psychiatry 2005; 62:1157-1164.
16. Broers B, Giner F, Damont P, Mino A. Impatient opiate detoxification in Geneva: Following-up at 1 and 6 months. Drug and Alcohol Dependence 2000; 58:85-92.
17. Chutuape M, Jasinski D, Fingerhood M, Stitzer M. One-, three-, and sixmonth outcomes after brief inpatient opioid detoxification. American Journal of Drug and Alcohol Abuse 2001; 27:19-44.
18. Hattenschwiler J, Ruesch P, Hell D. Effectiveness of inpatient drug detoxification: Links between process and outcome variables. European Addiction Research 2000; 6:123-131.
19. Wesson D. Buprenorphine in the treatment of opiate dependence: Its pharmacology and social context of use in the U.S. Psychoactive Drugs 1995; 2:119-128.
20. Chutuape M, Katz E, Stitzer M. Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug and Alcohol Dependence 2001; 61(2):137-143.
21. Mark T, Dilonardo J, Chalk M, Coffey R. Substance Abuse Detoxification: Improvements Needed in Linkage to Treatment. Report no. (SMA) 02-3728. Rockville, MD: Substance Abuse and Mental Health Service Administration, 2002.
22. Mark T, Dilonardo J, Chalk M, Coffey R. Factors associated with the receipt of treatment following detoxification. Journal of Substance Abuse Treatment 2003; 24(4):299-304.
23. Katz EC, Brown BS, Schwartz R, Weintraub E, Barksdale W, Robinson R. Role induction: A strategy for improving retention in outpatient drug-free treatment. Journal of Consulting and Clinical Psychology 2004; 72:227-234.
24. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992; 9:199-213.
25. Bickel W, Amass L, Higgins S, Badger G, Esch R. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology 1997; 65:803-810.
26. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DA, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. The American Journal of Addictions 2004; 13:S42-S66.
27. Amass L,Winhusen T, Harrer JM, Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment 2007; 32:349-356.